Source: Annual Congress 2002 - Cellular reactions in allergy in humans and animals
Disease area: Airway diseases

Abstract

It has previuosly been shown that airway allergen exposure induces enhanced eosinophil production, and increases the number of circulating CD34+ cells. Eosinophil (eos) develops from CD34+ progenitor cells, which proliferate and differentiate under the influence of IL-5. The aim of this study was to evaluate whether CD34+eos increases in the airways by airway allergen exposure, and whether a monoclonal antibody to IL-5 (TRFK5) would reduce any such effect. Method: OVA-sensitized and exposed on 5 days Balb/c mice were pre-treated with TRFK5 (50mg/animal) or its isotype control at different time-points of allergen exposure. BAL and bone marrow (BM) cells were collected 24h after the last exposure. CD34+eos numbers were examined by immunocytochemistry. Results: CD34+eos in BM were significantly reduced when TRFK5 was given on day 1, 2 or 3 of OVA exposure (1.15±]0.23; 2.30±]0.38; 4.25±]0.52% of total cells) versus vehicle treated mice (6.08±]0.46%, p<0.05). The same tendency was seen in BALf CD34+eos numbers, but without significant difference. After extension of the OVA exposure period up to 10 days, a further increase in CD34+eos numbers in both BALf and BM. A significant inhibitory effect was found on CD34+eos in BAL on the 5th day after TRFK5 administration and extended exposure period versus vehicle treated mice (0.98±]0.33 vs 15.89±]4.98x104/ml, p<0.01). 98% of eos in BALf after allergen exposure were CD34+. Conclusion: A single dose of anti-IL-5 rapidly decreases CD34+eos numbers in both BALf and BM.

Rating:

Share or cite this content

Citations should be made in the following way:
B. Sitkauskiene, M. Sjöstrand, C. Malmhäll, J. Lötvall (Kaunas, Lithuania; Gothenburg, Sweden). Anti-IL-5 antibody reduces the increase of CD34+ eosinophils in a mouse model of airway allergic eosinophilia. Eur Respir J 2002; 20: Suppl. 38, 297

Member's Comments

No comment yet.

Related content which might interest you: Induction of allergic bronchial hyperreactivity in DA-rats despite low-level eosinophilia in airways and lack of specific IgE antibodies Source: Annual Congress 2007 - Mouse models of allergic airway inflammation Year: 2007 The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001 Disruption of CD44 variant 6 abolished bronchial hyperresponsiveness, inflammation and mast cell myositis in a murine model of asthma Source: Eur Respir J 2006; 28: Suppl. 50, 217s Year: 2006 Comparison of anti-IL-9 and anti-IL-5 treatment efficacy in a mouse model of airway eosinophilic inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 482s Year: 2003 CCL6 produced by eosinophils drives allergic airway inflammation in mice Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 MMP-9 deficiency reduces airway inflammation and hyperresponsiveness in a mouse model of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001 Intratracheal instillation of anti-CD103 does not affect allergic airway inflammation in a mouse asthma model Source: Eur Respir J 2005; 26: Suppl. 49, 25s Year: 2005 Deficiency of MMP-19 promotes allergen-induced eosinophil burden and airway responsiveness in mice Source: Annual Congress 2007 - Regulation of allergic airway inflammation in animal models of asthma Year: 2007 Narirutin inhibits airway inflammation in an allergic mouse model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007 Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020 Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Relationship between allergen-induced increase of AHR to bradykinin, expression of the proliferation marker Ki-67 and eosinophils in bronchial mucosa of atopic asthmatics Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways Year: 2003 CAT-354, an IL-13-neutralising human monoclonal antibody, inhibits airways hyperresponsiveness and eosinophilia in a cynomolgus monkey model of allergen challenge Source: Eur Respir J 2005; 26: Suppl. 49, 232s Year: 2005 Intratracheal instillation of antigen-specific IgG ameliorated murine bronchial asthma via reduction of antigen presentation of airway dendritic cells Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008 Experimental specific immunotherapy with timpol decreases allergic sensitization and airway inflammation in murine model of bronchial asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 The development of an airway hyperresponsiveness (AHR) depends on mast cells following sensitization without adjuvant Source: Annual Congress 2006 - Cellular immunology in asthma pathogenesis Year: 2006